"
Template:UCSF/Head
From 2010.igem.org
| (33 intermediate revisions not shown) | |||
| Line 1: | Line 1: | ||
| + | {{Template:UCSF/subnav/Hello/BBB/AAA}} | ||
<html> | <html> | ||
| Line 8: | Line 9: | ||
#tocDIV{ | #tocDIV{ | ||
| - | margin-top: | + | margin-top:8px; |
| - | + | ||
} | } | ||
| Line 19: | Line 19: | ||
} | } | ||
#innertoc{ | #innertoc{ | ||
| - | |||
} | } | ||
| Line 66: | Line 65: | ||
y.id = 'innertoc'; | y.id = 'innertoc'; | ||
var a = document.createElement('a'); | var a = document.createElement('a'); | ||
| - | a.innerHTML="< | + | a.innerHTML="<b>Page Content -</b>"; |
a.id = 'contentheader'; | a.id = 'contentheader'; | ||
a.onclick = showhideTOC; | a.onclick = showhideTOC; | ||
| Line 81: | Line 80: | ||
var str = toBeTOCced[i].innerHTML; | var str = toBeTOCced[i].innerHTML; | ||
var result = reg.exec(str); | var result = reg.exec(str); | ||
| - | tmp.innerHTML = result; | + | tmp.innerHTML = result[1]; |
tmp.className = 'page'; | tmp.className = 'page'; | ||
z.appendChild(tmp); | z.appendChild(tmp); | ||
| Line 89: | Line 88: | ||
if (toBeTOCced[i].nodeName == 'H5') | if (toBeTOCced[i].nodeName == 'H5') | ||
tmp.className += ' extraindent'; | tmp.className += ' extraindent'; | ||
| - | var headerId = result[1] | + | var headerId = result[1]; |
tmp.href = '#' + headerId; | tmp.href = '#' + headerId; | ||
toBeTOCced[i].id = headerId; | toBeTOCced[i].id = headerId; | ||
| Line 358: | Line 357: | ||
</script> | </script> | ||
| - | <div style="float:left;width:710px" id="Main"> | + | <div style="float:left;width:710px;margin-top:5px; |
| + | background-image: url(http://gaips.inesc-id.pt/aamas2008/images/banner.jpg); | ||
| + | background-repeat:no-repeat;" id="Main"> | ||
<div id="navigation"> | <div id="navigation"> | ||
<ul> | <ul> | ||
| Line 411: | Line 412: | ||
</ul> | </ul> | ||
</div> | </div> | ||
| + | |||
| + | <div id="breadcrumbs"> | ||
| + | <nav> | ||
| + | <ul id="sub-navigation"> | ||
| + | <li class="first parent parent-1"><a href="https://2010.igem.org/Team:UCSF">Home</a></li> | ||
| + | </ul> | ||
| + | </nav> | ||
| + | </div> | ||
| + | <script>getLadder();</script> | ||
| + | |||
| + | <div style="background-color: #ede8e2;margin-top:160px;"> | ||
</html> | </html> | ||
| Line 426: | Line 438: | ||
<html> | <html> | ||
| - | + | </div> | |
</div> | </div> | ||
| Line 453: | Line 465: | ||
</div> | </div> | ||
| - | <div style="position:relative;height:auto;margin-top:8px;padding:10px;border:1px grey dashed;" id=" | + | <div style="position:relative;height:auto;margin-top:8px;padding:10px;border:1px grey dashed;" id="TOCC"> |
</div> | </div> | ||
| Line 462: | Line 474: | ||
function makeTOC(){ | function makeTOC(){ | ||
var toc=createTOC(); | var toc=createTOC(); | ||
| - | var tocdiv=document.getElementById(' | + | var tocdiv=document.getElementById('TOCC'); |
tocdiv.appendChild(toc); | tocdiv.appendChild(toc); | ||
} | } | ||
Latest revision as of 02:49, 10 October 2010
Project Description
Natural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death.
Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
Project1
Home
TOC
Hello
